2025
Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study
Prunas O, Tiu A, Shioda K, Bansal S, Weinberger D. Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study. Vaccine X 2025, 24: 100622. DOI: 10.1016/j.jvacx.2025.100622.Peer-Reviewed Original ResearchCOVID-19 patientsCase-control studyIntensive care unitSevere respiratory symptomsPneumococcal vaccineSevere outcomesRespiratory symptomsOdds of progressionReceipt of pneumococcal vaccinationCOVID-19 severitySevere COVID-19 outcomesLogistic regression modelsSevere acute respiratory syndrome coronavirus 2Streptococcus pneumoniaeAcute respiratory syndrome coronavirus 2Non-severeRespiratory syndrome coronavirus 2Care unitControlled studiesPatientsSyndrome coronavirus 2COVID-19 outcomesSARS-CoV-2VaccineCoronavirus 2
2024
BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Longlax S, Koster K, Kamat A, Lozano M, Lerner S, Hannigan R, Nishiguchi T, Abhimanyu, Sheikh D, Ladki M, Portillo A, Koirala A, Patel T, Spieler Z, Benjamin A, Lebedev M, Ofili T, Hutchison R, Udeani G, Opperman L, Neal G, Mandalakas A, Netea M, Arditi M, Avalos P, Grimm S, Coarfa C, Cirillo J, DiNardo A. BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infectious Diseases 2024, 12: ofaf007. PMID: 39872813, PMCID: PMC11770274, DOI: 10.1093/ofid/ofaf007.Peer-Reviewed Original ResearchVaccine immunityDNA methylation changesBCG-induced trained immunityClinical trialsBCG vaccinationPlacebo-controlled clinical trialStudy enrollmentAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 infectionCovid-19 specific vaccineMethylation changesCoronavirus 2 infectionCOVID-19 vaccine immunitySymptomatic COVID-19Secondary analysisSARS-CoV-2 antigensInnate immune responseDouble-blindPlacebo armBCG TiceTrained immunitySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Coronavirus immunityRespiratory syndrome coronavirus 2Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection
Majumdar S, Weaver J, Pontejo S, Minai M, Lu X, Gao J, Holmes G, Johnson R, Zhang H, Kelsall B, Farber J, Alves D, Murphy P. Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection. Journal Of Leukocyte Biology 2024, 117: qiae252. PMID: 39607906, DOI: 10.1093/jleuko/qiae252.Peer-Reviewed Original ResearchSARS-CoV-2 infectionSARS-CoV-2Mouse-adapted strain of SARS-CoV-2Absence of CXCL10Associated with poor outcomesCXCL10-/- miceLungs of male miceInflammatory gene inductionAcute SARS-CoV-2 infectionMouse-adapted strainSevere COVID-19Wild type controlsCXCL10-deficientChemokine CXCL10Lymphocytic infiltrationSevere acute respiratory syndrome coronavirus 2Poor outcomeAcute respiratory syndrome coronavirus 2Circulating levelsMale miceRespiratory syndrome coronavirus 2Infected miceSARS-CoV-2 pathogenesisVirus loadCXCL10Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
Carmo H, Castillo A, Bonilha I, Gomes E, Barreto J, Moura F, Davanzo G, de Brito Monteiro L, Muraro S, de Souza G, Morari J, Galdino F, Brunetti N, Reis-de-Oliveira G, Carregari V, Nadruz W, Martins-de-Souza D, Farias A, Velloso L, Proenca-Modena J, Mori M, Loh W, Bhatt D, Yellon D, Davidson S, De Oliveira P, Moraes-Vieira P, Sposito A. Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study. Frontiers In Pharmacology 2024, 15: 1402032. PMID: 39434905, PMCID: PMC11491754, DOI: 10.3389/fphar.2024.1402032.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsSARS-CoV-2 infectionSARS-CoV-2Viral replicationInflammatory responseInflammasome activationMarkers of inflammasome activationPlacebo-controlled studySuppress viral replicationBlood mononuclear cellsInfection in vitroPrimary metabolitesCOVID-19 patientsDouble-blindPrimary endpointHealthy volunteersSevere acute respiratory syndrome coronavirus 2Plasma markersAcute respiratory syndrome coronavirus 2Mononuclear cellsClinical trialsRespiratory syndrome coronavirus 2Day 2Syndrome coronavirus 2Human vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infection
Yang L, Han Y, Zhang T, Dong X, Ge J, Roy A, Zhu J, Lu T, Vandana J, de Silva N, Robertson C, Xiang J, Pan C, Sun Y, Que J, Evans T, Liu C, Wang W, Naji A, Parker S, Schwartz R, Chen S. Human vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infection. Cell Stem Cell 2024, 31: 1612-1629.e8. PMID: 39232561, PMCID: PMC11546835, DOI: 10.1016/j.stem.2024.08.007.Peer-Reviewed Original ResearchProinflammatory macrophagesActivation of proinflammatory macrophagesImmune cell changesCoxsackievirus B4Host damageAccumulation of proinflammatory macrophagesSingle-cell RNA sequencingMulti-omics platformsB cellsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Marker expressionViral infectionViral exposureSyndrome coronavirus 2Endothelial cellsCell changesRNA sequencingSARS-CoV-2MacrophagesCell damageAutopsy samplesOrganoidsPyroptosisPostinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report.
Auld S, Sheshadri A, Alexander-Brett J, Aschner Y, Barczak A, Basil M, Cohen K, Dela Cruz C, McGroder C, Restrepo M, Ridge K, Schnapp L, Traber K, Wunderink R, Zhang D, Ziady A, Attia E, Carter J, Chalmers J, Crothers K, Feldman C, Jones B, Kaminski N, Keane J, Lewinsohn D, Metersky M, Mizgerd J, Morris A, Ramirez J, Samarasinghe A, Staitieh B, Stek C, Sun J, Evans S. Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report. Annals Of The American Thoracic Society 2024, 21: 1219-1237. PMID: 39051991, DOI: 10.1513/annalsats.202406-651st.Peer-Reviewed Original ResearchConceptsPulmonary infectionTreatment of pulmonary infectionsLower respiratory tract infectionsLong-term morbidityRespiratory tract infectionsShort-term outcomesAberrant host responseBurden of morbidityReview potential mechanismsPulmonary complicationsTract infectionsPulmonary pathogensSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Causative pathogenRespiratory syndrome coronavirus 2Therapeutic strategiesSyndrome coronavirus 2Host responseInfectionMorbidityPotential mechanismsCoronavirus 2Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study
Xu L, Chen X, Yang X, Chen S, Yang M, Yuan Z, Chen R, Wang J, Jiang H, Xu J, Wang Y. Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study. Frontiers In Cellular And Infection Microbiology 2024, 14: 1392491. PMID: 39211792, PMCID: PMC11358093, DOI: 10.3389/fcimb.2024.1392491.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsCOVID-19 pneumoniaViral shedding timeRetrospective cohort studyShort-term prognosisTransplant recipientsClinical featuresAntiviral drugsAntiviral medicationsCohort studyShort-term renal functionAdministration of antiviral drugsAssociated with better therapeutic outcomesSevere COVID-19 pneumoniaConcurrent coronavirus disease 2019Diagnosis of COVID-19 pneumoniaTransplanted kidney functionStatistically significant reductionShedding timeRenal functionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Clinical symptomsKidney functionInitial symptomsPost–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy
Metz T, Reeder H, Clifton R, Flaherman V, Aragon L, Baucom L, Beamon C, Braverman A, Brown J, Cao T, Chang A, Costantine M, Dionne J, Gibson K, Gross R, Guerreros E, Habli M, Hadlock J, Han J, Hess R, Hillier L, Hoffman M, Hoffman M, Hughes B, Jia X, Kale M, Katz S, Laleau V, Mallett G, Mehari A, Mendez-Figueroa H, McComsey G, Monteiro J, Monzon V, Okumura M, Pant D, Pacheco L, Palatnik A, Palomares K, Parry S, Pettker C, Plunkett B, Poppas A, Ramsey P, Reddy U, Rouse D, Saade G, Sandoval G, Sciurba F, Simhan H, Skupski D, Sowles A, Thorp J, Tita A, Wiegand S, Weiner S, Yee L, Horwitz L, Foulkes A, Jacoby V. Post–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy. Obstetrics And Gynecology 2024, 144: 411-420. PMID: 38991216, PMCID: PMC11326967, DOI: 10.1097/aog.0000000000005670.Peer-Reviewed Original ResearchSARS-CoV-2 infectionSARS-CoV-2Clinical characteristicsSevere acute respiratory syndrome coronavirus 2Gastrointestinal symptomsAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Risk factorsPost-acute sequelae of severe acute respiratory syndrome coronavirus 2Syndrome coronavirus 2Acute SARS-CoV-2 infectionHistory of obesityMulticenter cohort studyAssociated with increased prevalenceMultivariate logistic regression modelPostexertional malaiseCoronavirus 2Median timeAcute infection severityLogistic regression modelsAcute infectionCohort studyPredominant symptomPrimary outcomeStudy visitsSPIKENET: An Evidence-Based Therapy for Long COVID
Elumalai N, Hussain H, Sampath N, Shamaladevi N, Hajjar R, Druyan B, Rashed A, Ramamoorthy R, Kenyon N, Jayakumar A, Paidas M. SPIKENET: An Evidence-Based Therapy for Long COVID. Viruses 2024, 16: 838. PMID: 38932130, PMCID: PMC11209161, DOI: 10.3390/v16060838.Peer-Reviewed Original ResearchCarcinoembryonic antigen-related cell adhesion molecule 1Murine hepatitis virus-1Post-acute sequelae of COVID-19SARS-CoV-2 variantsSARS-CoV-2Development of severe inflammationCell adhesion molecule 1Long-term complicationsAdhesion molecule 1Multiple organ damagePotential therapeutic benefitMultiple SARS-CoV-2 variantsEvidence-based therapiesSequelae of COVID-19ACE2 receptor-binding domainSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Severe inflammationTissue edemaOrgan damageRespiratory syndrome coronavirus 2Long COVIDMolecule 1Receptor-binding domainSyndrome coronavirus 2Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects
Sun C, Liu H, Ouyang Z, Ding J, Zhang Q, Ma H, Xu D, Zhang Q, Zhou R, Yang M, Hu W. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects. Expert Opinion On Investigational Drugs 2024, 33: 533-542. PMID: 38662639, DOI: 10.1080/13543784.2024.2347302.Peer-Reviewed Original ResearchArea under the curveAscending-dose studyFood effect studyHealthy subjectsPlacebo-controlled phase I studySARS-CoV-2Increased approximately dose-proportionallyPlasma concentrationsTreatment-related adverse eventsApproximately dose-proportionallyPhase I studyHigh-fat mealBroad-spectrum antiviral drugsPreclinical activityDose proportionalityDouble-blindPlacebo-controlledReport safetyDose groupSafety profileStandard mealAdverse eventsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract
Mao T, Kim J, Peña-Hernández M, Valle G, Moriyama M, Luyten S, Ott I, Gomez-Calvo M, Gehlhausen J, Baker E, Israelow B, Slade M, Sharma L, Liu W, Ryu C, Korde A, Lee C, Monteiro V, Lucas C, Dong H, Yang Y, Initiative Y, Gopinath S, Wilen C, Palm N, Dela Cruz C, Iwasaki A, Vogels C, Hahn A, Chen N, Breban M, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W, Grubaugh N. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2319566121. PMID: 38648490, PMCID: PMC11067057, DOI: 10.1073/pnas.2319566121.Peer-Reviewed Original ResearchConceptsInterferon-stimulated genesRespiratory infectionsStrains of influenza A virusTreatment of respiratory viral infectionsRespiratory virus infectionsInfluenza A virusMouse model of COVID-19Respiratory viral infectionsNeomycin treatmentExpression of interferon-stimulated genesUpper respiratory infectionInterferon-stimulated gene expressionLower respiratory infectionsBroad spectrum of diseasesAdministration of neomycinRespiratory viral diseasesDisease to patientsUpper respiratory tractIntranasal deliveryCongenic miceIntranasal applicationNasal mucosaSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2A virusDNA methylation in long COVID
Xiao Y, Vermund S. DNA methylation in long COVID. Frontiers In Virology 2024, 4: 1371683. DOI: 10.3389/fviro.2024.1371683.Peer-Reviewed Original ResearchDNA methylationSevere acute respiratory syndromeAcute coronavirus disease 2019Middle East respiratory syndromeLong-term sequelaeDNA methylation phenomenonLong COVIDPredictive of outcomeCombination of clinical signsAcute COVID-19DNA methylation markersVirus-host interactionsLong lasting persistenceSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Respiratory syndromeChronic symptomsEpigenetic phenomenaSyndrome coronavirus 2Evolving syndromeCoronavirus disease 2019Long COVID patientsSyndromeAcute respiratory syndromeSeroprevalence of IgM/IgG and Neutralizing Antibodies against SARS‐CoV‐2 in Unvaccinated Young Adults from Mexico Who Reported Not Having Had a Previous COVID‐19 Infection
Padilla-Bórquez D, Matuz-Flores M, Hernández-Bello J, Sánchez-Zuno G, García-Arellano S, Oregon-Romero E, Herrera-Godina M, González-Estevez G, Adan-Bante N, Rosas-Rodríguez J, Muñoz-Valle J. Seroprevalence of IgM/IgG and Neutralizing Antibodies against SARS‐CoV‐2 in Unvaccinated Young Adults from Mexico Who Reported Not Having Had a Previous COVID‐19 Infection. Canadian Journal Of Infectious Diseases And Medical Microbiology 2024, 2024: 8871439. PMID: 38384428, PMCID: PMC10881245, DOI: 10.1155/2024/8871439.Peer-Reviewed Original ResearchCOVID-19 infectionNeutralizing antibodiesSARS-CoV-2 infectionSARS-CoV-2Unvaccinated young adultsNo history of COVID-19Young adultsHistory of COVID-19 infectionAnti-SARS-CoV-2 antibodiesHistory of COVID-19Severe acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2No historyRespiratory syndrome coronavirus 2Asymptomatic casesSyndrome coronavirus 2Silent spreadAsymptomatic peopleCoronavirus disease 2019InfectionPercentage of individualsAntibodiesAntibody testCoronavirus 2COVID-19Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Ullah I, Escudie F, Scandale I, Gilani Z, Gendron-Lepage G, Gaudette F, Mowbray C, Fraisse L, Bazin R, Finzi A, Mothes W, Kumar P, Chatelain E, Uchil P. Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens. IScience 2024, 27: 109049. PMID: 38361624, PMCID: PMC10867665, DOI: 10.1016/j.isci.2024.109049.Peer-Reviewed Original ResearchDirect-acting antiviralsEfficacy of direct-acting antiviralsVirus clearanceSARS-CoV-2Bioluminescence imagingSuppressed viral loadK18-hACE2 miceRapid virus clearanceNeutralizing antibody treatmentSARS-CoV-2 clearanceEvaluate therapeutic efficacyCOVID-19 convalescent plasmaMonotherapy regimensCombinatorial regimensAntibody treatmentViral loadSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Lung pathologyPandemic potentialRespiratory syndrome coronavirus 2Therapeutic arsenalConvalescent plasmaTreatment efficacySyndrome coronavirus 2Dermatologic Changes in Experimental Model of Long COVID
Hussain H, Paidas M, Rajalakshmi R, Fadel A, Ali M, Chen P, Jayakumar A. Dermatologic Changes in Experimental Model of Long COVID. Microorganisms 2024, 12: 272. PMID: 38399677, PMCID: PMC10892887, DOI: 10.3390/microorganisms12020272.Peer-Reviewed Original ResearchMurine hepatitis virus-1Consistent with human studiesAbsence of hair folliclesPost-SARS-CoV-2 infectionHair folliclesAnti-inflammatory responseLong-term health repercussionsPulmonary complicationsFollicle lossDermal layerLiver dysfunctionKidney impairmentCutaneous findingsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Tissue destructionDermatological changesAcute stageCoronavirus disease-19Pathophysiological changesHuman studiesCollagen depositionSkin alterationsSyndrome coronavirus 2
2023
Progressive shingles in a toddler due to reactivation of Varicella Zoster vaccine virus four days after infection with SARS-CoV-2; a case report
Miller C, Taylor-Salmon E, Emuren L, Landry M, Gershon A, Miller G. Progressive shingles in a toddler due to reactivation of Varicella Zoster vaccine virus four days after infection with SARS-CoV-2; a case report. BMC Infectious Diseases 2023, 23: 854. PMID: 38057696, PMCID: PMC10698951, DOI: 10.1186/s12879-023-08809-5.Peer-Reviewed Original ResearchConceptsVaricella-zoster virusVZV reactivationVaccine-strain varicella-zoster virusSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Latent varicella zoster virusSymptomatic COVID-19 infectionRespiratory syndrome coronavirus 2SARS-CoV2 infectionSyndrome coronavirus 2COVID-19 infectionVaccine-type strainsSARS-CoV-2Vesicular rashPediatric patientsSignificant morbidityClinical syndromeCoronavirus 2Single doseCase reportGeneral populationMechanical traumaDisease processHZ casesPhysiologic stressVaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023
Lewis N, Zhu Y, Peltan I, Gaglani M, McNeal T, Ghamande S, Steingrub J, Shapiro N, Duggal A, Bender W, Taghizadeh L, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Wilson J, Qadir N, Chang S, Ginde A, Mohr N, Mallow C, Lauring A, Johnson N, Gibbs K, Kwon J, Columbus C, Gottlieb R, Raver C, Vaughn I, Ramesh M, Johnson C, Lamerato L, Safdar B, Casey J, Rice T, Halasa N, Chappell J, Grijalva C, Talbot H, Baughman A, Womack K, Swan S, Harker E, Price A, DeCuir J, Surie D, Ellington S, Self W, Calhoun N, Murthy K, Cravens J, Herrick J, McKillop A, Hoffman E, Graves A, Zayed M, Smith M, Scott B, Health W, Fisher T, Hurutado-Rodriguez M, Kruse T, Dunkley S, Perez G, Bychkowski A, Grefsrud T, Calhoun N, Murthy K, Herrick J, Smith M, Steingrub J, Kozikowski L, De Souza L, Ouellette S, Shapiro N, Bolstad M, Coviello B, Ciottone R, Devilla A, Grafals A, Higgins C, Ottanelli C, Redman K, Scaffidi D, Weingart A, Surie D, McMorrow M, DeCuir J, Lewis N, Harker E, Ellington S, Mehkri O, Mitchell M, Griffith Z, Brennan C, Ashok K, Poynter B, Duggal A, Busse L, Lohuis C, Stanley N, Zhang S, Prekker M, Frosch A, Hendrickson A, Douglas S, Hurreh K, Peltan I, Smith C, Marshall H, Hager D, Ali H, Phan M, Gong M, Mohamed A, Nair R, Chen J, Exline M, Karow S, Khan M, So M, Snyder C, Swoope G, Smith D, Lee B, Rasul A, Pathak M, Lewald Z, Wilson R, Khan A, Peña J, Briceno G, Ahmed C, Martinez J, Pocius E, Oh M, Hyde J, Gause S, Wilson J, Gordon A, Perez C, Lau L, Bekiroglu I, Tran C, Frankel T, Garner O, Chandrasekaran S, Ginde A, Douin D, Martinez A, Huynh D, Steinwand A, Sullivan A, Withers C, Mohr N, Zepeski A, Nassar P, Landers S, Nielsen K, Briggs N, Fairfield C, Peebles A, Mallow C, Rivas C, Martin E, Monto A, Lauring A, McSpadden E, Truscon R, Kaniclides A, Thomas L, Bielak R, Valvano W, Fong R, Fitzsimmons W, Blair C, Gilbert J, Papalambros L, Holz A, Johnson N, Srinivasan V, Crider C, Steinbock K, Paulsen T, Anderson L, Self W, Talbot H, Grijalva C, Jones I, Halasa N, Chappell J, Womack K, Rhoads J, Baughman A, Kampe C, Johnson J, Swan S, Johnson C, Zhu Y, Rice T, Casey J, Stubblefield W, Zhu Y, Short L, Ezzell L, Whitsett M, McHenry R, Hargrave S, Blair M, Luther J, Pulido C, Peterson B, Files D, Gibbs K, Landreth L, Hicks M, Parks L, Kwon J, Parikh B, McDonald D, Samuels C, Vogt L, O’Neil C, Valencia A, Hink T, Bychkowski A, Dunkley S, Fisher T, Grefsrud T, Hurutado-Rodriguez M, Perez G, Beney K, Jayaprakash R, Koneru S, Lava J, Pinderi Z, Resk M, Goyal A, DeLamielleure L, Kosover M, Brokowski C. Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023. Clinical Infectious Diseases 2023, 78: 1056-1064. PMID: 38051664, PMCID: PMC11487098, DOI: 10.1093/cid/ciad677.Peer-Reviewed Original ResearchInfluenza-associated hospitalizationsVaccine effectivenessOrgan failureInfluenza vaccineSevere acute respiratory syndrome coronavirus 2Current season influenza vaccinationAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Influenza-associated outcomesInvasive mechanical ventilationAcute respiratory illnessSentinel Surveillance NetworkTest-negative designSyndrome coronavirus 2Close antigenic matchInfluenza vaccinationRespiratory failureRenal failureInfluenza seasonMechanical ventilationOrgan supportSupplemental oxygenRespiratory illnessCoronavirus 2Influenza circulationPolymer nanoparticles deliver mRNA to the lung for mucosal vaccination
Suberi A, Grun M, Mao T, Israelow B, Reschke M, Grundler J, Akhtar L, Lee T, Shin K, Piotrowski-Daspit A, Homer R, Iwasaki A, Suh H, Saltzman W. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Science Translational Medicine 2023, 15: eabq0603. PMID: 37585505, PMCID: PMC11137749, DOI: 10.1126/scitranslmed.abq0603.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Lethal viral challengeAntigen-presenting cellsSyndrome coronavirus 2Humoral adaptive immunityLung-targeting deliveryIntranasal vaccinationMucosal vaccinationPulmonary diseaseMucosal vaccinesSusceptible miceCoronavirus 2Viral challengeAdaptive immunityLungTranslational potentialMessenger RNA (mRNA) therapeuticsVaccinationMRNADeliveryTherapeuticsRNA therapeuticsTherapeutic deliveryGenome-wide CRISPR screens identify noncanonical translation factor eIF2A as an enhancer of SARS-CoV-2 programmed −1 ribosomal frameshifting
Wei L, Sun Y, Guo J. Genome-wide CRISPR screens identify noncanonical translation factor eIF2A as an enhancer of SARS-CoV-2 programmed −1 ribosomal frameshifting. Cell Reports 2023, 42: 112987. PMID: 37581984, DOI: 10.1016/j.celrep.2023.112987.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Host factorsSARS-CoV-2 replicationSyndrome coronavirus 2SARS-CoV-2Eukaryotic translation initiation factor 2ACoronavirus 2Viral RNAGenome-wide CRISPR screenFactor 2APositive-strand RNA virusesGenome-wide CRISPRRNA virusesKnockout screensRNAInitiationComputational Prediction of the Interaction of Ivermectin with Fibrinogen
Vottero P, Tavernini S, Santin A, Scheim D, Tuszynski J, Aminpour M. Computational Prediction of the Interaction of Ivermectin with Fibrinogen. International Journal Of Molecular Sciences 2023, 24: 11449. PMID: 37511206, PMCID: PMC10380762, DOI: 10.3390/ijms241411449.Peer-Reviewed Original ResearchConceptsSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Acute COVID-19Coagulation factor fibrinogenSyndrome coronavirus 2Interactions of ivermectinBlood coagulation factor fibrinogenSARS-CoV-2 spike proteinAbnormal blood clotsAntiparasitic drug ivermectinLong COVIDFactors fibrinogenCoronavirus 2Proinflammatory activityClot propertiesPathologic thrombosisClot formationBlood clotsDrug ivermectinIvermectinFibrinogen peptidesFibrin clotsCOVID-19
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply